Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204421985> ?p ?o ?g. }
- W3204421985 endingPage "147" @default.
- W3204421985 startingPage "140" @default.
- W3204421985 abstract "For the first time, derivatives of 3,7-diazabicyclo[3.3.1]nonane (bispidine) were proposed as potential inhibitors of the SARS-CoV-2 main viral protease (3-chymotrypsin-like, 3CLpro). Based on the created pharmacophore model of the active site of the protease, a group of compounds were modeled and tested for activity against 3CLpro. The 3CLpro activity was measured using the fluorogenic substrate Dabcyl-VNSTLQSGLRK(FAM)MA; the efficiency of the proposed approach was confirmed by comparison with literature data for ebselen and disulfiram. The results of the experiments performed with bispidine compounds showed that 14 compounds exhibited activity in the concentration range 1–10 μM, and 3 samples exhibited submicromolar activity. The structure–activity relationship studies showed that the molecules containing a carbonyl group in the ninth position of the bicycle exhibited the maximum activity. Based on the experimental and theoretical results obtained, further directions for the development of this topic were proposed." @default.
- W3204421985 created "2021-10-11" @default.
- W3204421985 creator A5001944497 @default.
- W3204421985 creator A5007253565 @default.
- W3204421985 creator A5017773589 @default.
- W3204421985 creator A5018927507 @default.
- W3204421985 creator A5019544912 @default.
- W3204421985 creator A5022526235 @default.
- W3204421985 creator A5032293800 @default.
- W3204421985 creator A5047171704 @default.
- W3204421985 creator A5050528480 @default.
- W3204421985 creator A5064320191 @default.
- W3204421985 creator A5068410324 @default.
- W3204421985 creator A5069266438 @default.
- W3204421985 creator A5070331301 @default.
- W3204421985 creator A5080665457 @default.
- W3204421985 creator A5080673162 @default.
- W3204421985 creator A5082061021 @default.
- W3204421985 creator A5087504643 @default.
- W3204421985 date "2021-09-29" @default.
- W3204421985 modified "2023-09-29" @default.
- W3204421985 title "Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors" @default.
- W3204421985 cites W1557255258 @default.
- W3204421985 cites W2005383616 @default.
- W3204421985 cites W2068176961 @default.
- W3204421985 cites W2082983886 @default.
- W3204421985 cites W2140137539 @default.
- W3204421985 cites W2294283371 @default.
- W3204421985 cites W2347165636 @default.
- W3204421985 cites W2417286343 @default.
- W3204421985 cites W2553602294 @default.
- W3204421985 cites W2799884888 @default.
- W3204421985 cites W2905203588 @default.
- W3204421985 cites W3007386177 @default.
- W3204421985 cites W3009970748 @default.
- W3204421985 cites W3011422148 @default.
- W3204421985 cites W3011701533 @default.
- W3204421985 cites W3013223828 @default.
- W3204421985 cites W3013282133 @default.
- W3204421985 cites W3014852814 @default.
- W3204421985 cites W3016885747 @default.
- W3204421985 cites W3020300207 @default.
- W3204421985 cites W3021989042 @default.
- W3204421985 cites W3023464695 @default.
- W3204421985 cites W3023838751 @default.
- W3204421985 cites W3023894494 @default.
- W3204421985 cites W3025480423 @default.
- W3204421985 cites W3026189060 @default.
- W3204421985 cites W3026282994 @default.
- W3204421985 cites W3033778153 @default.
- W3204421985 cites W3040116040 @default.
- W3204421985 cites W3047359420 @default.
- W3204421985 cites W3080596815 @default.
- W3204421985 cites W3082067818 @default.
- W3204421985 cites W3090085076 @default.
- W3204421985 cites W3090894484 @default.
- W3204421985 cites W3092541273 @default.
- W3204421985 cites W3093650985 @default.
- W3204421985 cites W3094104502 @default.
- W3204421985 cites W3111372677 @default.
- W3204421985 cites W3123135309 @default.
- W3204421985 cites W3123245089 @default.
- W3204421985 cites W3130155181 @default.
- W3204421985 cites W3131767541 @default.
- W3204421985 cites W3148554359 @default.
- W3204421985 cites W3167095072 @default.
- W3204421985 cites W4247555443 @default.
- W3204421985 doi "https://doi.org/10.1021/acsmedchemlett.1c00299" @default.
- W3204421985 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35043075" @default.
- W3204421985 hasPublicationYear "2021" @default.
- W3204421985 type Work @default.
- W3204421985 sameAs 3204421985 @default.
- W3204421985 citedByCount "26" @default.
- W3204421985 countsByYear W32044219852022 @default.
- W3204421985 countsByYear W32044219852023 @default.
- W3204421985 crossrefType "journal-article" @default.
- W3204421985 hasAuthorship W3204421985A5001944497 @default.
- W3204421985 hasAuthorship W3204421985A5007253565 @default.
- W3204421985 hasAuthorship W3204421985A5017773589 @default.
- W3204421985 hasAuthorship W3204421985A5018927507 @default.
- W3204421985 hasAuthorship W3204421985A5019544912 @default.
- W3204421985 hasAuthorship W3204421985A5022526235 @default.
- W3204421985 hasAuthorship W3204421985A5032293800 @default.
- W3204421985 hasAuthorship W3204421985A5047171704 @default.
- W3204421985 hasAuthorship W3204421985A5050528480 @default.
- W3204421985 hasAuthorship W3204421985A5064320191 @default.
- W3204421985 hasAuthorship W3204421985A5068410324 @default.
- W3204421985 hasAuthorship W3204421985A5069266438 @default.
- W3204421985 hasAuthorship W3204421985A5070331301 @default.
- W3204421985 hasAuthorship W3204421985A5080665457 @default.
- W3204421985 hasAuthorship W3204421985A5080673162 @default.
- W3204421985 hasAuthorship W3204421985A5082061021 @default.
- W3204421985 hasAuthorship W3204421985A5087504643 @default.
- W3204421985 hasBestOaLocation W32044219851 @default.
- W3204421985 hasConcept C181199279 @default.
- W3204421985 hasConcept C185592680 @default.
- W3204421985 hasConcept C18903297 @default.
- W3204421985 hasConcept C2776714187 @default.